Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios

• Published in: Molecular cancer therapeutics Vol. 23; no. 1; pp. 84 - 91
• Main Authors: Clardy, Susan M., Uttard, Alex, Du, Bingfan, Catcott, Kalli C., Lancaster, Kelly L., Ditty, Elizabeth, Sadowsky, Jack, Zurita, Jeffrey, Malli, Naniye, Qin, LiuLiang, Bradley, Stephen P., Avocetien, Kenneth, Carter, Tyler, Kim, Dokyong, Nazzaro, Mark, Xu, Ling, Pillow, Thomas H., Zacharias, Neelie T., Lewis, Gail D., Rowntree, Rebecca K., Iyengar, Radha, Lee, David H., Damelin, Marc, Toader, Dorin, Lowinger, Timothy B.
• Format: Journal Article
• Language: English
• Published: United States 03.01.2024
• Subjects: Cysteine; Humans; Immunoconjugates - chemistry; Receptor, ErbB-2 - metabolism; Trastuzumab - chemistry; Trastuzumab - pharmacology; Xenograft Model Antitumor Assays

Key defining attributes of an antibody–drug conjugate (ADC) include the choice of the targeting antibody, linker, payload, and the drug-to-antibody ratio (DAR). Historically, most ADC platforms have used the same DAR for all targets, regardless of target characteristics. However, recent studies and...